Calvillo-Argüelles O, et al. - Given that statins can reduce the risk of anthracycline-induced cardiotoxicity, researchers investigated such cardio-protective effects in retrospectively identified consecutive women with HER2+ breast cancer who received trastuzumab with or without anthracyclines. They assessed final left ventricular ejection fraction (LVEF) as the primary outcome. They evaluated the link between statin exposure and the final LVEF by using ANCOVA. Also, the link between statin exposure and cardiotoxicity (secondary outcome) was assessed by constructing a logistic regression model. A lower risk of cardiotoxicity was observed in association with concomitant statin use in women with HER2+ breast cancer receiving trastuzumab-based therapy with or without anthracyclines.